Anti-Human ACVR2A & ACVR2B Recombinant Antibody

Product Information

Catalog Number	YR1301
Product Name	Anti-Human ACVR2A & ACVR2B Recombinant Antibody
Molecular Name	Bimagrumab
Alias	Anti-ACVR2A & ACVR2B Recombinant Antibody, Research Grade Bimagrumab
CAS Number	1356922-05-8
Target	ACVR2A & ACVR2B[Homo sapiens]
Isotype	IgG1 Lambda
Clonity	Monoclonal
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Applications	FCM, IP, ELISA, Neut, FuncS, IF, ICC, MRI
Buffer	PBS, pH7.5
Background	Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price